Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to present the...
Source: Roche Media News - June 13, 2020 Category: Pharmaceuticals Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to present the...
Source: Roche Investor Update - June 13, 2020 Category: Pharmaceuticals Source Type: news

Leukemia immune profiles predict drug resistance and benefits of immunotherapy
(American Association for the Advancement of Science) By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), researchers have identified new immune classes of the disease that predict the likelihood of drug resistance and positive responses to immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2020 Category: Cancer & Oncology Source Type: news

$2 million SBIR grant fast-tracks cancer drug platform technology
(Purdue University) A $1,999,998 SBIR Phase I/II grant from the National Institute of Cancer to KinaRx LLC, a Purdue University-affiliated startup, will help fast-track to human trials a novel platform aimed at treating relapse for acute myeloid leukemia and other diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2020 Category: Cancer & Oncology Source Type: news

Courtney DiNardo, MD, on Need for Improved, Effective Regimens in IDH1-Positive AML
The MD Anderson Cancer Center expert discussed why there is an unmet need for more treatments in patients with IDH1-mutated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Courtney DiNardo, MD Source Type: news

AMG 330 Appears Safe, Tolerable in Relapsed/Refractory Acute Myeloid Leukemia
The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML
(University of Texas M. D. Anderson Cancer Center) A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Genetic Factors in AML With Myelodysplasia-Related Changes Genetic Factors in AML With Myelodysplasia-Related Changes
This study explored the clinical significance of three subcategories of AML-MRC.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Dexrazoxane Preserved Cardiac Function in Children Undergoing Chemotherapy for AML
A study found that dexrazoxane, a cardioprotective drug, preserved cardiac function without compromising overall survival and event-free survival for pediatric patients with acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma. Longer-term follow-up results from the Phase 1b portion of the study (n=29), to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #8505), show that ...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

AML:'Start as Oncology Patients, but Return With Heart Damage'AML:'Start as Oncology Patients, but Return With Heart Damage '
Children treated for acute myeloid leukemia are often cured of their cancer but return years later with hearts damaged by therapy. Cardioprotection with dexrazoxane could help, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Dexrazoxane Preserves Cardiac Function in Pediatric Leukemia
TUESDAY, May 12, 2020 -- For pediatric patients with acute myeloid leukemia (AML), dexrazoxane preserves cardiac function without affecting survival, according to a study published online April 28 in the Journal of Clinical Oncology. Kelly D. Getz,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 12, 2020 Category: Pharmaceuticals Source Type: news

EU Panel OKs Glasdegib for AML & Luspatercept for MDS EU Panel OKs Glasdegib for AML & Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 1, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

EU Panel OKs Glasdegib for AML and Luspatercept for MDS EU Panel OKs Glasdegib for AML and Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news